Details

Autor(en) / Beteiligte

• Cepeda-Franco, Carmen
• Mitxelena-Iribarren, Oihane
• Calero-Castro, Francisco José
• Astigarraga, Malen
• Castillo-Tuñon, Juan M
• Laga, Iman
• Pereira, Sheila
• Arana, Sergio
• Mujika, Maite
• Padillo-Ruiz, Javier

Titel

TARTESSUS : A Customized Electrospun Drug Delivery System Loaded with Irinotecan for Local and Sustained Chemotherapy Release in Pancreatic Cancer

Ist Teil von

• Bioengineering (Basel), 2023-02, Vol.10 (2), p.183

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Post-surgical chemotherapy in pancreatic cancer has notorious side effects due to the high dose required. Multiple devices have been designed to tackle this aspect and achieve a delayed drug release. This study aimed to explore the controlled and sustained local delivery of a reduced drug dose from an irinotecan-loaded electrospun nanofiber membrane (named ) that can be placed on the patients' tissue after tumor resection surgery. The drug delivery system formulation was made of polycaprolactone (PCL). The mechanical properties and the release kinetics of the drug were adjusted by the electrospinning parameters and by the polymer ratio between 10 w.t.% and 14 w.t.% of PCL in formic acid:acetic acid:chloroform (47.5:47.5:5). The irinotecan release analysis was performed and three different release periods were obtained, depending on the concentration of the polymer in the dissolution. The device was tested in 2D and 3D cell cultures and it demonstrated a decrease in cell viability in 2D culture between 72 h and day 7 from the start of treatment. In 3D culture, a decrease in viability was seen between 72 h, day 7 ( < 0.001), day 10 ( < 0.001), 14 ( < 0.001), and day 17 ( = 0.003) as well as a decrease in proliferation between 72 h and day 10 ( = 0.030) and a reduction in spheroid size during days 10 ( = 0.001), 14 ( < 0.001), and 17 ( < 0.001). In conclusion, showed a successful encapsulation of a chemotherapeutic drug and a sustained and delayed release with an adjustable releasing period to optimize the therapeutic effect in pancreatic cancer treatment.